Immunization of human HIV-seronegative volunteers with recombinant p17/p24:Ty virus-like particles elicits HIV-1 p24-specific cellular and humoral immune responses.

Journal article

OBJECTIVE: To evaluate the immune response to HIV-1 p24 generated in vivo by p17/p24:Ty virus-like particles (p17/p24:Ty-VLP) by examining the lymphoproliferative and antibody (Ab) responses to HIV-1 p24, as well as Gag-specific cytotoxic T lymphocytes (CTL), in HIV-seronegative volunteers immunized with hybrid p17/p24:Ty-VLP. DESIGN AND METHODS: Sixteen HIV-seronegative volunteers were immunized with p17/p24:Ty-VLP at two dose levels (100 or 500 micrograms) and monitored for the following 48...

Expand abstract

Authors: Martin, S; Vyakarnam, A; Cheingsong-Popov, R; Callow, D; Jones, K

• Publication status: Published
• Journal: AIDS (London, England)
• Volume: 7
• Issue: 10
• Pages: 1315-1323
• Publication date: 1993-10-01
• DOI: 10.1097/00002030-199310000-00003
• EISSN: 1473-5571
• ISSN: 0269-9370
• Language: English
• Keywords: AIDS Vaccines; T-Lymphocytes, Cytotoxic; gag Gene Products, Human Immunodeficiency Virus; Recombinant Proteins; HIV-1; Male; HIV Seronegativity; HIV Antibodies; Viral Proteins; Humans; HIV Core Protein p24; HIV Antigens; Gene Products, gag